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Abstract
Intellectual property, particularly patents, plays a major role in innovation and discovery
in biotechnology. Likewise, since the passage of the Bayh-Dole Act in 1981, patents have
become an increasingly important factor in U.S. university-driven basic research,
especially in the life sciences where patented technologies have transformed agriculture.
Specifically, this paper looks at the potential impacts of these trends on university driven
research, the university researcher, the pharmaceutical industry, and the farm sector with
an emphasis on recent and pending court cases and legislation. This paper examines
policy and adoptions issues in biotechnology and biomedicine in depth and touches on
important developments in the tech sectors as a back drop for pending legislation and
recent court rulings. How policy is adopted, implemented and interpreted have profound
impacts on food production, medical ethics, ecology, U.S. and international farm and
innovation sectors and the competiveness of the U.S. in the global economy.
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Introduction
Patents have become an important part of the university research process. Since the
passage of the Bayh-Dole Act, large universities that receive federal funding for research
have been required to actively seek patents on new technologies and license those
technologies to the private sector. The purpose of the legislation was to help ensure that
those discoveries funded by federal dollars made it into the hands of the public and were
not destined to remain obscure or even abandoned.
The relatively recent pursuit of patents and income-generating licensing fees has
created tensions for public universities in particular because their discoveries are partially
underwritten by state dollar investment as well. Additionally, the trend to patent both by
public universities and privates firms has placed a strain on the United States Patent and
Trademark office, creating a backlog of patent applications and generating patent thickets
in biotechnology, semiconductors and other arenas. Not surprisingly, strong patent
protection from the courts has resulted in large damages awards, further muddying the
waters and creating a cottage industry for firms that do not invent, yet profit from patent
litigation.
Several groups have risen in the past decade to look at the special problems
arising from intellectual property, particularly as it relates to food and medicine
development. The U.S. Congress has been attempting to reform patent laws to address
many of these issues, and the court system has been responding as well. This thesis looks
at some very specific problems arising from these tensions, including: the likelihood of
infringement suits against university researchers; the possible consequences of patent
reform on the pharmaceutical industry; the rise and potential fall of glyphosate (arguably
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the most widely-adopted patented agricultural product in history); and finally a guide to
help early career professor understand the patent system with an eye to helping them
make informed decisions about how to navigate the increasingly complex research
landscape.
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Chapter 1 Patents: Are university researchers at risk?

(This chapter was published in Nature Biotechnology (2007) 25: 1225–8 with the
following authors: Amy Yancey and C. Neal Stewart, Jr.)

Amy Yancey was the principal author of the manuscript.

Abstract
Researchers at public universities face many challenges from anticommons effects in
agricultural-and other biotechnologies. By and large academic researchers have ignored
patents on key technologies as a strategy to maneuver around patent thickets and FTO
issues, but they may be more at risk than they realize. There seems to be no legal
impediment from patent holder prosecution of professors, students, postdocs and other
researchers who are regular infringers.

Patent purpose and history
Hippodamus is credited with first suggesting that states should reward innovators for
introducing useful products to society in Aristotle’s Politics [1]. The basic idea is
grounded in the tenants of utilitarianism, “reward the creator of a useful thing, and
society will gain more useful things.” Aristotle had reservations, even at that early date,
about the tension between serving public good and rewarding individuals. Patents have
played a significant role in Western civilization and the notions of progress since the late
1400s. In the United States, patents have been an important part in innovation and
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science, but how could people in the 19th century and earlier envisioned biotechnology
and today’s research climate?

Anything under the sun
The statute language has changed little since 1793. “Whoever invents or discovers any
new and useful process, machine, manufacture, or composition of matter, or any new and
useful improvement thereof, may obtain a patent therefore [2].” However, patent policy is
still evolving through the interpretation of the courts and the United States Patent and
Trademark Office (USPTO) and through legislation. Modern interpretations of the patent
statute have changed to more precisely define utility, disclosure, enablement, novelty,
nonobviousness and even the technical statutory bars, but the single most important
change for biotechnology came from the landmark Diamond v. Chakrabarty decision on
patentable subject matter. The Supreme Court decision allowed for patents on living
microorganisms with the majority deciding that Congress intended patentable subject
matter to “include anything under the sun that is made by man [3].” The Chakrabarty
ruling has important implications for utility patents on plants and the evolution of
agricultural biotechnology. Plants were originally only eligible for protection under the
Plant Patent Act of 1930 or the Plant Variety Protection Act of 1970, but now utility
patents are regularly granted on plants and related processes. A cursory search of plantrelated utility patents shows that patents filed under the USPTO’s plant classification
have increased steadily from five in 1981 to 777 in 2006. Anecdotally at least, this would
seem to suggest that granting utility patents on plants has indeed spurred innovation in
that field.
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Promoting progress or encouraging infringement?
Despite the apparent increase in plant utility patents in the past 25 years, private
agricultural biotechnology research and development seemed, unexpectedly, to peak in
the mid- to late-1990s [4]. This apparent discrepancy results from a number of complex
issues, including industry consolidation through the formation of life sciences
conglomerates. It has been suggested that one underlying reason seems to come from
patent thickets and anticommons effects that arise from the patenting of basic research
processes in agricultural biotechnology—essentially creating a situation conducive to
market failure where innovation is invariably blocked because of the cost of bringing
downstream technologies to market [5,6,7]. While a recent report from the Science and
Intellectual Property in the Public Interest (SIPPI) project concludes that innovation
blocking is not occurring, the matter is far from settled in the biotechnology sector [8].
The survey relies on the self-reporting of researchers, asking them how licensing of
protected technologies were acquired and the effects of IP difficulties on research in their
laboratories. It does not measure any effect on downstream technologies. Furthermore, an
earlier report to the National Academy of Sciences suggests that at least part of the reason
university research has not been impacted is because of regular infringement of patents
by university researchers, which is neither a sustainable nor desirable solution [9].
Patent thickets occur from the patenting of enabling or platform technologies in
certain fields such as biotechnology, semiconductors and software and result in
difficulties in navigating the patent landscape [5]. Patents may be overly broad, blocking,
or be held by rival companies who wish to exclude competitors from the market. Also,
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while patents and patent applications are disclosed, license agreements are often not. Add
to the mix defensive patenting, a complex and difficult USPTO classification system, and
a lack of information available on the license status of certain technologies, and it
becomes difficult to know what privately-developed technologies are available for use by
researchers. Furthermore, because patents rights are negative rights, bestowing only the
right and obligation to exclude others from making, using, selling, or importing the
invention, patent holders are not required to utilize the invention—only to defend it—
potentially resulting in the underutilization of important tools for addressing public
welfare factors in food and fiber production, the casualties of which may be humanitarian
and environmental benefits. Commonly referred to as the ‘tragedy of the anticommons’,
the effect was first described by Michael Heller and then applied to research issues by
Heller and Rebecca Eisenberg in 1998 [6]. The tragedy arises when rational individuals,
acting separately, underutilize a scarce resource to the detriment of all. As applied to
patents, the anticommons effect is the result of too many firms having the right to exclude
others from a scarce resource to the detriment of the public good (contrasted with the
tragedy of the commons where a common resource is over-utilized). Essentially,
scientific advance is blocked if the cost of licensing-enabling technologies exceeds the
potential value of a product when public researchers are barred from accessing
proprietary technologies. And since 76 percent of agricultural biotechnology patents are
held by private firms, public researchers have been and will continue to be denied official
access to important technologies [7]. Worse, simply determining where a researcher has
freedom-to-operate (FTO) is becoming more difficult—with important implications for
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infringement, particular since patent infringement happens routinely in every university
with biotechnology research.
Examples of thickets and anticommons at work in agricultural biotechnology
include broad patents on the two most reliable and utilized plant transformation
techniques. Monsanto’s patent on the process of transforming plants through the use of
Agrobacterium tumefaciens is claimed so broadly it could exclude all plant
transformation processes that use any engineered bacteria to transfer foreign DNA into
plant genomes. The other method, biolistics-mediated transformation, was developed by
Cornell University, but licensed exclusively to DuPont, who has blocked competitors
from accessing the technology [7, 1]. Similar issues for other enabling technologies exist.
Monsanto also holds the patent on the neomycin phosphotransferase (nptII) gene, one of
the most commonly used selectable markers, which confers antibiotic resistance in
transformed plant material. The patent, though set to expire in 2008, has claims written so
broadly as to cover all methods of conferring antibiotic resistance even though recent
discoveries have produced less controversial methods that rely on plant versus bacterial
mechanisms, which raise concerns among critics who fear exacerbation of antibiotic
resistance issues REF [11].
Another important example of thicket problems is illustrated in the much-cited
Golden Rice project. The provitamin A-enhanced rice was developed for humanitarian
purposes to combat blindness and malnutrition in developing nations. Developing the rice
required access to over 40 U.S. patented technologies [12]. Since there is no commercial
value in creating humanitarian crops, it would have been economically infeasible to
produce had companies not waived their license fees for the project.
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While it is disturbing to consider anticommons effects on agricultural research,
the repercussions are equally distressing in biomedical research, where similar problems
arise. For instance, the genes BRCA1 and BRCA2 have recently been associated with
hereditary breast cancer. A diagnostic procedure for identifying the genes was licensed
exclusively to Myriad Genetics, who went so far as to block testing by a University of
Pennsylvania researcher [13, 6]. The fast-paced software and semiconductor industries
also face similar difficulties. Solutions in those arenas may prove helpful to addressing
innovation-stifling problems in agricultural biotechnology.

Why should researchers care about patent policy?
On principle
In the US, the land-grant university (LGU) system was established in 1862 through the
Morrill Act and later expanded through several acts to include mandates for research and
cooperative extension. At the core of the values of the LGU system is the idea that public
investment in education, research and outreach results in public benefits. Much of the
basic research that has led to current patents on research tools were created by or in
collaboration with publicly-funded university research or, at the very least, on the
shoulders of over 100 years of public investment and developmental policy in agricultural
research. Anecdotal evidence demonstrates that patents on those tools can be and are
being used to block further research on downstream technologies that could save lives
and serve the public well-being. Furthermore, important humanitarian and fair trade
issues arise. Golden Rice is only one example of how patent thickets can pose difficulties
in bringing improved nutrition to developing countries. In addition, numerous ethical
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concerns arise when private companies have the capacity to exploit traditional knowledge
of peoples in the developing world for profit, especially if they exclude those peoples
from a share of proceeds or access to the benefits of additional discoveries derived from
that knowledge. Perhaps the most complex ethical consideration arises over the blurring
of our definition of products of nature versus products of man. The Supreme Court’s
failure to grant certiorari in the recent Metabolife case, which grants a patent on a basic
scientific relationship, seems to suggest that FTO issues will only become increasing
difficult for public researchers in the quest who seek to understand basic natural
relationships for the public good [14].

Having our cake and patenting it, too
The Bayh-Dole Act of 1980 urges research institutions, including universities, to own
inventions from federally-supported research and to license those technologies to the
private sector [15]. Institutions are required to adopt formal patent polices for employees,
seek patent protection on new technologies, and encourage the development of those new
technologies [16]. Bayh-Dole adds to layers of complexity to the problems posed for
public university researchers. There have been several significant instances in which a
technology developed at the university level was licensed exclusively to a private
company to the exclusion even of the researchers who invented it. And as universities
continue to encourage and sometimes push scientists to produce transferable technology
and reap income from license agreements and start-up successes, it becomes, arguably,
less defensible for those researchers to infringe with impunity. Furthermore, it’s unclear
whether or not public researchers are accountable for infringement even if they do not

9

commercialize any technology as a result of research efforts. Could university professors
performing basic research be successfully sued for infringing patents?
Many university scientists tend to ignore patents [9]. In today’s climate where
technologies are at the crux of science, it is unforeseeable that professors could
successfully perform any meaningful research without infringing patents. But they do so
at their own peril. While patent statute contains a clearly-stated research exemption, the
2002 court decision in Madey v. Duke limits the scope of the research exemption to
experiments done “solely for amusement, to satisfy idle curiosity, or for strictly
philosophical inquiry [17].” Madey was not a company, but instead a disgruntled exfaculty member, but the case has important implications for universities and their
researchers. The court found that the precedent did “not immunize any conduct that is in
keeping with the alleged infringer's legitimate business, regardless of commercial
implications.” Essentially, major research universities often conduct research projects
without commercial application, but that research still advances the institution's
educational mission to “increase the status of the institution and lure lucrative research
grants, students and faculty.” It is hardly for amusement.

Future consequences?
In private universities, the answer is made clear by Madey v. Duke. They can be sued for
making, using, selling, or importing patented technologies, even if they have no intention
of commercializing the fruits of the research. For public universities, Eleventh
Amendment sovereign immunity rules apply in intellectual property cases; for now
anyway. The four dissenting Supreme Court justices in the narrowly decided Florida
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Prepaid case raised concerns over state institutions benefiting from intellectual property
without being required to honor it [18]. This puts public universities in the proverbial
tight spot between Bayh-Dole (on the Congressional side) and the potential loss of
immunity (on the Judicial side). At the time, the ruling in favor of immunity prompted
Congress to propose new legislation to close what they saw as a loophole in IP protection
issues [19]. For now, sovereign immunity stands.
Also yet to be decided is the question of whether or not individual university
researchers can be held liable for infringement. There certainly exists no clear precedent
suggesting that they cannot be. Let us consider here recent cases in which the music
industry has pursued university students for downloading copyrighted material since they
cannot pursue immune public universities for failing to curtail the downloading—this is
contrasted with the now infamous Napster case where the record industry effectively shut
down Napster in 2001 instead of pursuing individual violators. Just because a researcher
has not been sued does not mean he or she will not be in the near future. And if a
researcher has stake in a commercial start-up company that is spun-out of university
research, she or he may be in for a rude surprise. In fact, infringement need not be direct.
Indirect infringement might be brought against a third party for helping Party A infringe
Party B’s patent. And willful infringement—usually avoided by private firms by
conducting thorough FTO searches—can incur treble damages.

Good for the goose…
When and where might industry nip? The May 2007 Iowa State University Research
Foundation suit against Monsanto alleges Monsanto willfully infringed on their low-
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linolenic acid soybean and seeks treble damages [20]. Ultimately, as universities and
researchers continue to actively pursue patent protection for inventions under Bayh-Dole,
the line between business and public welfare becomes increasingly fuzzy and may in fact
provide the impetus for private firms to aggressively protect their patents, especially as
universities commercialize tools through license agreements or develop downstream
products of commercial interest.

Emerging solutions
While the public forum seems the obvious place for reform, important barriers exist that
may make solutions slow in coming, if they come at all. Recent Federal Circuit Court
decisions seem to suggest a trend toward stronger protection for patents and other IP. The
World Trade Organization’s Trade Related Aspects of Intellectual Property Rights
agreement (TRIPS) echoes the United States’ emphasis on desiring stronger IP protection
for all member countries. Congress has been slow to reform, even on procedural issues
such as implementing a U.S. first-to-file system, but both the House and Senate have
patent reform legislation bills to consider this year. Much of the special interest pressure
comes from a private sector that is not uniform in opinion on resolving patent problems
(patentlyo.com), but tends to lean toward stronger IP protection. On the regulatory side,
the USPTO is understandably pro-patent. Still, recent innovations may help prevent
overly-broad or nonobvious patents from being issued as the USPTO prepares to launch
the first ever trial on a peer-to-patent process using a wiki where experts can comment on
patent applications (www.uspto.gov). It also remains to be seen what effect the
unanimous April Supreme Court ruling on KSR International, Co. vs. Teleflex, Inc. will
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have in reducing the number of broad and obvious patents. The decision promises to
allow more flexibility in applying the ‘teaching, suggestion or motivation test’ and
consequently should allow examiners and courts more flexibility in determining that a
patent is obvious to one skilled in the art [21, 22].
The market is responding as well. Several private companies are providing
services designed to help steer clients to information and access to patented technology,
some free. PatentMonkey.com offers free database searching and charges fees for more
extensive services. LegalForce just recently launched an online marketplace that may
prove useful in licensing, buying, selling and trading patented technologies. Several nonprofits are also specializing in helping underserved communities in the developing world.
Both LightYears, IP and Public Interest Intellectual Property Advisors offer volunteer
expertise to help countries develop and protect IP. The Coalition for Patent Fairness is an
advocacy group working to reform innovation-stifling practices and address patent
litigation issues.
The best solutions may be yet to come. One relatively recent, but promising,
development is the formation of open-source movements to pool patents, provide
improved databases and search capacities, and develop “workarounds”. The movement,
inspired by the software open-source movement, was begun by Richard Jefferson with
the founding of CAMBIA. While critics point out the obvious—that unlike software
development, biotechnology is not likely to be practiced in the garage [23]—open
movements may be gaining ground. CAMBIA, which is “change” in Spanish, has several
initiatives for fostering open-source solutions for issues in food security, health, and
natural resource management in disadvantaged communities and developing countries
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(www.cambia.org). One of the organization’s primary goals is to develop and encourage
development of enabling technologies through BioForge. Participants are free to use
these technologies under open-license agreements that allow them to be used without fee
so long as subsequent advances are made freely available. CAMBIA has already made
strides toward producing efficient workarounds, including the Transbacter method for
biological transformation of plants without using Agrobacterium. CAMBIA also has
tools for enhancing open collaboration among scientists including Patent Lens, which
uses database capacities to make the patent landscape more transparent, and BiOS, a
system designed to help foster collaboration by scientists in an open community.
The Public Intellectual Property Resource for Agriculture (PIPRA) is another
organization taking cues from open-source in the hope of improving access to agricultural
intellectual property. PIPRA’s goal is to “make agricultural technologies more easily
available for development and distribution of subsistence crops for humanitarian
purposes in the developing world and specialty crops in the developed world”
(www.pipra.org). Headquartered at the University of California, Davis, PIPRA has
worked to create special licensing language for humanitarian use and has also developed
a searchable database of agricultural patents with over 6600 international patents in it.
They are working on a plant transformation vector with maximal FTO and have just
released an IP handbook that should help public researchers navigate the considerably
murky waters of patent protection (www.IPhandbook.com). Based in part on the work
PIPRA has done, some major research institutions such as the University of California
have moved to include exceptions for public research in their license agreements and
member institutions are following suit.
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Conclusions
The original proponents of patent protection could not have foreseen a world where the
very building blocks of life could be patented or farmers could be prevented from saving
seeds from year to year, but our courts, regulators and political leaders are certainly
aware of it now. Despite this fact, public policy solutions are slow in materializing and
problems may get worse before they improve. It may prove that no silver bullet exists,
but that with open-source solutions, pressure from open science advocates like Richard
Jefferson, and open licensing from universities, anticommons effects can hopefully be
avoided or minimized. In the interim, it seems prudent to conduct research on awareness
of FTO issues by public university researchers, increase empirical evidence of the
innovation-blocking effects of anticommons and patent thickets, and evaluate the
effectiveness of those organizations seeking to increase collaboration among public
institutions and create workarounds.
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Chapter 2 Patent Reform in the United States: What’s at stake for pharmaceutical
innovation?

(This chapter was published in Expert Opinion on Therapeutic Patents ( 2010) 20 (5): 6038 with the following authors: Amy Yancey and C. Neal Stewart, Jr.)

Amy Yancey was the principal author of the manuscript.

Abstract
The current patent landscape in the United States has not undergone major legislative
reform since 1952. The U.S. Senate version of the most recently proposed patent reform
legislation proposes a number of rule changes that could impact the pharmaceutical
industry. Among the bill’s major provisions are moving to a first-to-file system, changes
to post-grant review and reexamination procedures, and damages reform. Various
industries with a stake in patent policy have responded to the proposed changes, but the
stakes are particularly high for pharmaceutical industry which must invest a significant
amount of time and money in the research and development (R&D) process in exchange
for already abbreviated patent lifetimes due to the lengthy clinical trial process.

Introduction
In the United States, the idea that inventors should gain exclusive rights to their
innovations was written into the Constitution and passed into law in 1790 [1, 2]. The
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purpose of granting exclusive rights to inventors is to help foster innovation for the
benefit of the public good. In the U.S., patent rights are a tradeoff—the inventor shows
the world how the invention works in exchange for the right to exclude others from
making, using or selling the patented technology for a limited period of time. In the U.S.,
this limited period of time is typically the longer of 20 years from filing or 17 years from
the date of issue [3]. The belief that patents spur innovation is widely accepted, but not
without controversy. In fact, over the past hundred years, support for strong IP protection
has cycled substantially [4]. Over the past 30 years, patent rights have enjoyed
considerable growth as indicated in Figure 1.

Figure 1. Patent grants and applications in the U.S. since 1963.
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The Bayh-Dole Act, passed in 1980, requires universities and others using federal
funding to seek patents on their inventions and to license those technologies when
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possible to industry [5]. That same year, the Supreme Court decision in Diamond v.
Charkrabarty expanded the definition of patentable subject matter to include “anything
under the sun that is made by man [6].” And in 1981, Congress created the Court of
Appeals for the Federal Circuit specifically to hear patent cases. With combined changes
to the patent landscape came the predictable and intended boom in the race to patent [7].
The proliferation of patents has resulted in a number of conflicting issues for different
fields including an overwhelmed patent office with a backlog of 718,835 applications (as
of December 2009), patent thickets in the biotechnology and semiconductor fields, and
the rise of non-manufacturing entities (NMEs), also called non-practicing entities (NPEs),
in the high-tech sector [8, 9, 10]. These issues have begun to create barriers to innovation
with long lead times on application reviews from the United States Patent and Trademark
Office (USPTO) and evidence of anticommons effects in certain industries [11]. The
outcry has been significant enough in the past five years to prompt Congress to attempt to
significantly reform patent law for the first time in over 50 years, beginning with
proposed legislation in 2005 [12].

Not all industries are equal
The pharmaceutical industry has much at stake in U.S. patent law reform. The
pharmaceutical sector faces a unique set of challenges that combines large initial R&D
expenditures, long lead times from patent application to product release, pressure from
non-innovator firms (generic industry), and shortened patent protection due to the lengthy
clinical trial process [13]. Pharmaceutical impacts are uniquely important. The industry is
especially dependent on high research costs on the front end, and arguably relies on
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‘blockbuster drugs’ to recoup those costs [14]. Central to the issue among analysts is the
fear that if firms believe they cannot recoup their investment through strong patent
protection, they will spend less time researching and creating new and safe therapies—
with important implications for human health. And though far from the only factor to
determine the ability of the pharmaceuticals to recoup their investments, it is a critical
one [15].

Pharmaceutical firms have already seen erosions in the effective life of their patents. It
takes an average of seven years to complete clinical trials, essentially limiting patent
protection to 11.5 years [16]. The Hatch-Waxman Act further complicates the therapeutic
landscape. Passed in 1984, it was created to bring generic, and consequently cheaper,
drugs to market faster by creating a research exemption that further reduces the effective
life of patented therapies [17]. Additionally, the 2007 KSR v. Teleflex decision could
impact the controversial practice of “evergreening” patented medicines by making minor
improvements in their effectiveness more difficult to patent [18, 19].

The Proposed Reform
In March 2009, U.S. Senators Hatch and Leahy introduced the Patent Reform Act of
2009 [20]. The bill (S. 515) is the fourth recent attempt to enact the first significant
changes to U.S. patent law since 1952. The bill, as drafted, pits the interests of the high
tech sectors against those of biotechnology and pharmaceutical innovators [21, 22]. High
tech firms fear high litigation costs and being tied up in lengthy litigation with NMEs
(often called patent trolls). They also often find technologies are obsolete by the time
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patents issue [23]. Conversely, pharmaceutical firms want longer, stronger patent
protection to protect their substantial investments [24]. Initially, reform was primarily
intended to reconcile U.S. and international patent systems, but the current bill is drafted
to change the U.S. to a first-to-file system, make it easier to challenge patentability and
validity outside the courts, and reduce and clarify damages awards [25]. While the bill
did not pass in 2009, it is sure to resurface, particularly due to the strong support for
many of the proposed changes from multiple public and private sectors, including the
American Association of Universities and high tech firms.

Overview of the major provisions of the bill
First-to-file
The U.S. system is unique among developed countries in that the statute supports a firstto-invent system, allowing inventors to “swear behind” the point of conception in
interference proceedings where two similar patent applications are being prosecuted
through the USPTO. Basically, this means that the applicant who can prove he or she first
conceived of invention is granted priority over other applicants. The proposed legislation
changes the rule. The first party to file an application on a new invention has priority over
other applicants, doing away with the need for interference proceedings entirely [26]. The
bill would eliminate the year-long grace period for disclosure of the innovation unless the
disclosure was made by the inventor. The proposed legislation reconciles U.S. procedure
with the European and Japanese models. The change does not have particular
implications for pharmaceutical patents specifically, but should spur inventors in all
sectors to file for application as soon as possible.
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Post-grant review, reexamination and pre-issuance submissions
The Senate bill also proposes changes to post-grant review of issued patents, allowing
any party to challenge a new patent within 12 months of issuance, based on any grounds
for invalidity (except best mode). Previously post-grant review was based only on
evidence of prior art. Reexaminations are also expanded, based on published prior art or
prior public sale or use in the U.S. The bill proposes limits to the number of challenges a
third party can make. Parties are estopped from requesting inter partes reexamination
requests after a district court has already ruled on validity. The new legislation also
allows third parties to submit prior art and publications with comment on patent
applications during examination. These rule changes in particular will make patentability
and validity easier to challenge.

Damages
The most contentious provision in the bill proposes changes to limit damage awards to
consideration of “specific contributions over prior art [27].” Courts must decide if the
valuation of a patented invention falls under one of three categories. “Entire market
value” is when the infringing device or product is based predominantly on a single patent.
“Marketplace licensing” is when damages determinations are based on a royalty for
licensing a similar substitute. It is important to note here that if the similar substitute is in
the public domain, this formulation could reduce damages to zero. “Value calculation”
bases damages only on the portion of the economic value derived from what the
invention contributes over the prior art.
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Venue reform
Among the specific proposed changes in S. 515 is the requirement that suits be brought
in states where the plaintiff has a physical place of business, is incorporated, or has an
established facility. The legislation would prevent filers from incorporating in certain
regions solely for the purpose of bringing suit in preferred, plaintiff-friendly courts such
as the Eastern District of Texas.

Willful infringement
The bill also codifies tougher criteria for willful infringement (which incurs treble
damages) in keeping with recent court decision In re Seagate Technology, LLC [28]. The
bill creates a criterion of “objective recklessness” to incur treble damages. The infringer
must have received written notice of the infringement, intentionally copied the patented
technology or previously been found to be infringing. Also, if the infringer acted in “good
faith” demonstrating that they believed the patent was invalid, unenforceable or not
infringed, they are exempted from willful infringement.

What’s at stake? University and industry response
The most recent version of the legislation garners strong support from universities and
high tech firms. Universities have responded positively to the fact that lawmakers are
incorporating the recommendations by the National Academies of the Sciences [29].
There is strong sentiment among academics who study patent policy that anticommons
effects are starting to adversely affect innovation, particularly in the biotech and high tech
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sectors. They cite increasing evidence that the landscape is becoming too difficult to
navigate and that the USPTO is overwhelmed and issuing patents that fail to meet the
criteria for patentability [30]. Table 1 shows the backlog of applications in the USPTO by
technology sector.
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Table 1. Patent backlog by technology sector.
Number
Applications Awaiting First Office Action by Examiner

Applications

of
Examiners

Total

718,835

6,143

Tech Center 1600 - Biotechnology & Organic Chemistry

60,836

532

Tech Center 1700 - Chemical and Materials Engineering

87,136

730

60,882

629

39,669

698

127,956

875

123,122

1,056

83,535

766

116,522

744

3,606

113

Tech Center 2100 - Computer Architecture, Software &
Information Security
Tech Center 2400 - Network, Multiplexing, Cable & Security
Tech Center 2600 - Communications
Tech Center 2800 - Semiconductor, Electrical, Optical
Systems & Components
Tech Center 3600 - Transportation, Construction, Agriculture
& Electronic Commerce
Tech Center 3700 - Mechanical Engineering, Manufacturing
& Products
Tech Center 4100 - Patent Training Academy
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High tech firms view themselves as defendants. They are happy to avoid treble damages,
plaintiff-friendly courts, and the mire of patent thickets. Their support stands in sharp
contrast to the pharmaceutical and biotechnology industries, who largely see themselves
as plaintiffs forced to enforce their right to exclude [31, 32]. These sectors have long lead
times, particularly pharmaceutical companies. Industry analysts are concerned that
reduced damages will reduce or nullify the deterrent to infringe by competitors. The
Pharmaceutical Research and Manufacturers of America (PhRMA) states in its official
response to S. 515 that “by lowering the penalties for those found by a court to have
infringed another’s patent, the bill would reduce the value of the patents that are the
lifeblood of America’s innovative business sectors, which depend on intellectual property
protection [33].” The biotech industry has also come out with strong objections to
proposed changes to damages calculations in the bill [34].

Expert Opinion
Patent rights have grown substantially over the past 30 years, and with the strengthening
of those rights has come expansion. With the passing of the Bayh-Dole, the Chakrabarty
decision, and creation of the Federal Circuit, patent applications, patent grants, and patent
litigation have all grown at a rapid pace. This same period has seen a boom in
pharmaceutical research, biotechnology, and high tech industries. Only the recent
economic downturn stopped a 13 year trend in increased patent applications [35]. This
period of growth has led to unintended consequences—a bogged down USPTO and a
proliferation in some sectors where pro-patent effects stunt innovation and prevent
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products from coming to market. Lawmakers are seeking to address those issues with
one-size fits all legislation, but finding consensus among different industries is critical. In
fact, a new book by Dan Burk and Mark Lemley, The Patent Crisis and How the Courts
Can Solve It, argues that the courts are the best place for some reforms in light of the
varying needs of different industries [36]. The proposed legislation as a whole,
particularly considering the changes to damages calculations, weakens patent rights in an
environment where recent court decisions have already eroded patent protections for the
pharmaceutical sector. There can be little doubt that if the proposed legislation passes as
is, pharmaceutical companies will find both that their patent holdings less valuable and
more difficult to defend. . New legislation is critically needed. Law makers will continue
to be pressed to address some of the very real and serious problems facing the U.S.
innovation sector sooner rather than later. But Congress must not rush to pass legislation
that favors high tech over pharmaceutical and biotechnology industry concerns,
particularly as it relates to damages reform. There is still much work to do to avoid
unintended consequences that could reduce the number of new and potentially life-saving
therapies coming to market. Legislators should continue to work with industry and
university stake holders across all major technological sectors to ensure that any
legislation passed does not forsake innovation in one field for another.
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Chapter 3 Saving glyphosate: A multi-pronged approach to managing glyphosate
resistance in weeds

Abstract
The first confirmed glyphosate-resistant horseweed was discovered in the United States
in 2001 in Tennessee and Mississippi. Since that time, eight major crop weeds have been
added to the list across the country. Glyphosate and gylphosate-resistant crops represent
the single most important and rapidly-adopted innovation in modern agriculture.
Glyphosate is uniquely important among herbicides. It is economical for farmers, safe in
the environment, effective against a broad spectrum of weeds, and facilitates
conservation agriculture. It has facilitated mass production of major crops and saved
farmers billions of dollars, literally helping the U.S. and other agricultural production
countries feed the world. With over 90 percent of soybean, 68 percent of corn, and 70
percent of cotton in the US containing transgenic resistance to glyphosate, the loss or
even reduced effectiveness of glyphosate for the control of weeds will have potentially
devastating impacts on farm income and the environment. Scientists and corporations are
exploring and recommending a variety of solutions, but without significant efforts to
raise both farmer awareness of and adoption of recommendations aimed at stewarding
glyphosate, it may prove difficult to save this crucial herbicide for long-term use.
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Introduction
Glyphosate resistant (GR) crops have been the most rapidly adopted new crop trait in the
history of world agriculture [1]. With that rapid adoption has come the pervasive and
almost exclusive use of glyphosate as a weed control mechanism. According to the
United States Department of Agriculture’s Economic Research Service (USDA-ERS),
over 136 million acres were planted with GR crops in 2009 in the U.S. Glyphosate is also
used extensively for burn down of weeds before planting non-GR crops, sprayed along
roadways, and used extensively to control residential and sports turf weeds. With the rise
of glyphosate use has come the unintended selection of resistant weeds. Glyphosate
resistant weeds pose a serious threat to world food production, U.S. agriculture and the
environment. No other herbicide offers the same unique qualities that make glyphosate so
desirable, and none are poised to replace it in the foreseeable future. University
researchers and life sciences companies have long been looking for solutions in the
laboratory and in the field and sounding the alarm. There are multiple recommendations
for mitigating resistance, but farmers are largely unaware of both the threat and the
methods for slowing the spread of resistance in crop weeds. Furthermore the economic
and convenience advantages of glyphosate may deter even well-versed farmers from
adopting stewardship recommendations and/or new, more expensive technologies until
they experience weed pressure first hand. By then it may be too late.

Glyphosate and resistant crop technology
Glyphosate is a revolutionary and unique chemical herbicide first commercialized in the
mid-1970s and best known under the brand name Roundup® by Monsanto. Glyphosate’s
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special status among herbicides comes primarily from its mode, or mechanism, of action.
Glyphosate inhibits an important plant enzyme, 5-enylpryuvylshikimate-3-phosphate
synthase (EPSPS), blocking the production of important amino acids, phenylpropanids,
tannins and lignins [2]. Because EPSPS is found only in plants and certain bacteria, and
because glyphosate binds tightly in the soil, breaking down into natural material over
time, it has extremely low toxicity and an excellent environmental profile [3, 4]. These
traits, combined with break-through glyphosate-resistant (GR) crop technologies, ease of
use, low price and positive impact on farm income have made glyphosate and associated
crop technologies the most important agricultural chemical of the past 100 years with its
impact on world food production likened to the discovery of penicillin [5].
A major scientific break-through occurred in 1983 with the successful isolation of
the CP4 strain of Agrobacterium tumefaciens which was highly tolerant of glyphosate
and led to the successful insertion of the cp4 epsps gene [6]. In 1996, Monsanto released
the first commercial transgenic crop with the GR event. The Roundup® Ready soybean
allowed growers to treat crops post-emergently with glyphosate, providing convenience,
promoting no-till practices and positively impacting farm income [7]. Soon after, many
transgenic varieties were rapidly adopted in the U.S. As of 2009, over 91 percent of all
soybean is glyphosate-resistant. Other GR crops quickly followed. Now over 68 percent
of corn and 71 percent of cotton are glyphosate-resistant. GR canola and sugarbeet have
also been commercialized and adopted. Newer transgenic crop varieties have been
introduced with higher levels of resistance have been stacked with other transgenic traits
like insect resistance [6].

34

The rapid adoption of GR technologies has been a boon to major U.S. crops and
has subsequently been adopted in other countries, particularly in the Americas. The widespread use of glyphosate has had major economic and environmental benefits [7].
Furthermore, the widespread adoption of glyphosate as a post-emergent herbicide has
resulted in energy savings and soil conservation from the adoption of no-till agriculture.
And glyphosate is far more environmentally-friendly than other broad-spectrum
herbicides. Glyphosate resistant technologies have transformed agriculture and food
production in a world where exploding human population continually stretches food
resources. Any threat to the effectiveness of glyphosate is a threat to U.S. agricultural
production, the environment and world food production.

Clear and present – Glyphosate resistant weeds
Glyphosate-resistant horseweed was first observed in Mississippi and Tennessee in 2001.
Horseweed escapes were reported in soybean fields that were treated at the recommended
rates both preplant and post-emergent. Laboratory testing of seeds collected from the
escapes showed 8-fold to 12-fold resistance over susceptible biotypes [8]. Since those
early studies, Palmer amaranth, common ragweed, fleabane, waterhemp, giant ragweed,
Italian ryegrass, rigid ryegrass, and Johnsongrass have all emerged in the U.S. with
glyphosate resistance [9]. In March 2010, the first confirmed resistant giant ragweed was
reported in Canada [10]. The problem will continue to intensify if sustainable practices
are not rapidly adopted.
Glyphosate has been used around the world for over 35 years, but with the
unprecedented adoption of GR crops since 1996 came the dramatically different use
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pattern resulting in reduced weed-control diversity and strong and persistent use of
glyphosate. With the adoption of successful GR crops, use of other herbicides
diminished. Glyphosate is not only much more effective and environmentally safe, it is
comparatively much more economical than other herbicides because it can be cheaply
produced as a generic [11]. Also, crop rotation between GR soybean and GR corn also
means that many fields are being treated twice a year, every year [12]. Also, glyphosate
has facilitated conservation no-till farming practices, another key way to control for
weeds. This increased (and sometimes constant) selection pressure has led to the
emergence of weeds that persist even at recommended rates of application.
Both industry and academic researchers have poured a significant amount of time
and resources in to solutions to slow or stem the spread of glyphosate resistance in weeds.
There are numerous academic papers dedicated to the study of the issue. There is a major
industry working group, the Herbicide Resistance Action Committee (HRAC), dedicated
to the problem [15]. Ian Heap also operates a survey site (www.weedscience.com)
monitoring the spread of specific weeds with funding and support from HRAC, the North
American Herbicide Resistance Action Committee (NAHRAC), and the Weed Science
Society of America (WSSA) . Monsanto operates a weed resistance website
(www.weedresistancemanagement.com) with farmer recommendations and Monsanto
and Pioneer have already developed crops with stacked transgenic resistance to other
mechanisms [6]. Solutions for stewarding glyphosate fall into three main overlapping
categories: more research into weed genomics and modes of resistance, crops with new
GR mechanisms and stacked resistance, and diversification of weed management
practices at the farm level.
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More basic genomic research needs to be done at the university level to better
understand non-target resistance to herbicides, especially glyphosate. Only a few
resistance genes have been cloned and characterized in weeds [13]. Major modes of
glyphosate resistance in weeds include alteration of EPSPS, which decreases the ability
of glyphosate to bind to the enzyme, and the unanticipated reduced translocation of
glyphosate to the roots and growing points of the plant [12, 13]. Reduced translocation is
not a common mechanism for herbicide resistance, and a better understanding of this
mechanism in resistant biotypes might lead to discovery of novel strategies for improving
translocation. [13]
Several newly discovered technologies are currently being developed and/or
commercialized that could both help mitigate GR weed problems and facilitate
diversification of herbicide use. New glyphosate-resistance mechanisms have recently
been discovered, including a newly discovered class of EPSPS enzymes with much
higher resistance in corn, allowing for spraying at up to eight times the recommended
field rate [6]. Another strategy, gene stacking varieties for resistance to multiple
herbicides, should help facilitate diversification. Among the promising new stacks are
glyphosate with ALS resistance. Other events that show promise for stacking with
glyphosate resistance, or in some cases that are already in development, include:
glufosinate, accase, auxin and dicamba resistance; HPPD-, and PPO-inhibiting herbicide
resistance; and P450 metabolic resistance [6, 14]. In particular, glufosinate, which has no
known resistant weeds, could be very effective, as could HPPD inhibitors which also has
no known resistant weeds and soil residual activity comparable to glyphosate [6].

37

Facilitating adoption of diverse weed-management practices
While scientists have been tracking glyphosate-resistant weeds in earnest since 1997 and
companies have been actively working to mitigate effects and develop new technologies,
the farm sector has surprisingly little awareness of the magnitude of the problem. A
major 2009 survey of farmer awareness, showed that only 30 percent of farmers thought
GR weeds were a serious threat and that most did not understand that recurrent use of the
same herbicide was the primary mechanism for the development of resistant populations
[1]. Most farmers believe that a new herbicide will be developed before GR weeds
become a major problem. Since the 1960s, the number of compounds that needed to be
screened to yield a single product has grown exponentially. Likewise, most of the known
herbicide modes of action (MOA) involve enzyme inhibition. A few disrupt other
processes such as cell division or auxin response, but no new MOA has been discovered
since sulcotrione was introduced in 1991 [13]. No herbicides with new modes of action
are currently on the horizon. The authors of the aforementioned survey also noted that
information has been disjointed and confusing to farmers who are more likely to get
information from the farm press than other sources that may only present part of the story
or fail to make strong recommendations, finally recommending that a consistent message
relaying the seriousness of the problem and recommendations for farmers come from
universities, farmers groups, corporations and governments. A new National Academy of
the Sciences (NAS) study on transgenic crops concludes that weed problems will become
increasingly problematic as a result of herbicide and glyphosate resistance. The NAS
study similarly recommends a concerted effort from all sectors and stakeholders [16].
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Another major concern that needs to be studied is the willingness of farmers to
adopt new technologies and glyphosate-conservation practices even if they are aware of
the magnitude of the problem. A substantial amount of research has been done on the
willingness of farmers to adopt new technologies and conservation practices, and suggest
farmers can be slow to act [17]. GR crops are convenient, familiar and economical. Until
farmers actually experience serious weed competition on a personal level, it seems
questionable that they will invest in the time, equipment and additional chemical and seed
costs to institute sustainable practices, particularly since the least educated group
consisted of small, part-time farmers, the group least likely to assume perceived risks of
adopting new practices. By then, it may be too late to save glyphosate. Additional
research needs to be undertaken to determine the extent of what farmers are willing invest
in time and money to adopt sustainable practices. It seems likely that without special
incentives, education will only be the first hurdle. Monsanto may be best poised to
influence farmers to make changes in seed and chemical applications because of their
market share, but with a recent anti-trust investigation from the Justice Department, their
influence may soon wane [18].

Conclusions
Glyphosate use in conjunction with GR crops represents the most important advance in
agriculture production, and with it comes the ability to keep pace with increased food
demand from a rising world population. GR crops have had an overwhelmingly positive
effect on farm income in the U.S. and glyphosate remains one of the safest and
environmentally-friendly agronomic advances used in modern agricultural production.
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The loss or even reduced effectiveness of glyphosate could have devastating impacts on
U.S. agriculture and the world food production. Yet despite overwhelming and
conclusive evidence that glyphosate-resistant weeds are a major threat, little has been
done to send a consistent message to the farm sector. University and corporate
researchers have been hard at work, monitoring the advance of GR weeds and identifying
effective ways to slow their advance. Life sciences companies have several products in
development that could replace or supplement existing GR crops. Continued research will
point to novel ways to address resistant weeds and the development of newer
technologies, but without education and resrouces, it seems unlikely that farmers,
particularly small, part-time farmers, will adopt newer, more expensive practices or
technologies to fight GR weed spread. A concerted effort to educate farmers needs to be
undertaken as NAS suggests, but more will likely be needed. Incentives for adoption of
new practices and technologies may need to be implemented to encourage farmers to
investment time and money before they personally experience significant problems from
GR weeds, at which point it may be too late.
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Chapter 4 Patent uncertainty: A primer for university researchers in the life
sciences

Abstract
Recent pressure from industry, universities and research groups has resulted in increased
pressure on the U.S. Congress to pass patent reform legislation. The U.S. Court of
Appeals for the Federal Circuit (Federal Circuit) and the U.S. Supreme Court have
recently decided several landmark cases that address specific issues impacting the
technology sectors. These recent court rulings and proposed legislation have important
consequences for the life sciences, and in particular, important implications for
biotechnology. Recent articles have focused on particular cases or issues, but very little in
recent literature provides a comprehensive overview of the patent system at large with an
eye to the way recent and proposed changes effect the university researcher.

Introduction
Special consideration is given to the life sciences when it comes to intellectual property.
Large investments of time and money make patent protection especially crucial as an
incentive to the development of innovations [1]. Additionally, these sectors face patent
thickets and problems from overly broad, overlapping and poorly-claimed patents [2, 3].
Ethical and humanitarian considerations further complicate the complex landscape of
patents in biotechnology and biomedical sectors [3]. Changes to the patent system have
several purposes: reconciling U.S. patent law and international patent policy; addressing
extensive backlogs in the system and related problems such as poor patent quality; and
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clarifying statutory rules for patent eligibility. Many of the changes specifically address
problems, sometimes very polarized, in the technology sectors and have particular
implications for biotechnology [1]. A thorough review of the literature reveals that there
is little available that provides researchers with context for recent and proposed changes
or a practical guide for what impacts, if any, the changes would likely have on a
researcher’s process for disclosing his or her invention. There is a need for both an
overview of the role of patents in university research and an overview of what impacts
recent and proposed changes will have on biotechnology as researchers make decisions
about whether or not their discoveries are patentable and whether or not they should be
patented.

What is a patent?
A patent is a type of intellectual property that covers “new and useful” inventions [4].
Intellectual property rights are considered negative rights because they exclude or limit
others’ use of those new ideas or inventions. Patent rights specifically exclude others
from making, using or selling the invention [5]. An important caveat for researchers is
that, unlike copyright protection, there is no “fair use” clause. In other words? The
exclusion of rights extends to academic use and all but the narrowest of research
exemptions [3].
Patents can be categorized as sanctioned, limited-duration monopolies, with the
first formal system dating back to fifteenth-century Europe. Congress’s power to extend
intellectual property rights to inventors was drafted by the framers of the U.S.
Constitution [6]. Justification for exclusive rights to certain types of ‘products of the
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mind’ is added incentive for inventors to bring the invention to light for the benefit of
society. For patents, the trade for the exclusion of other makers is both disclosure and
enablement of the invention. In other words—the inventor must show the world how the
invention works. Other statutory criteria for patent eligibility are subject matter, novelty,
nonobviousness and utility. These criteria are codified into U.S. statutory law, but are
dynamic and evolving as clarified through case law [6].
In addition to the lack of a functional research exemption, another important
distinction university researchers should note is that unlike authorship, an inventor must
have had a substantial hand in bringing the invention to light. Simply being hands-on
does not make a lab technician or graduate student a co-inventor, and improperly
attributing inventor status invalidates the patent [6]. Also, in university settings as in
corporate settings, the inventor usually assigns rights to his or her employer’s designee.
Many universities have a separate technology transfer entity, often a foundation or
corporation, to which ownership of the invention is assigned [7, 8].

Origins of U.S. Patent System

The basic tenets of modern patent law can be traced to fifteenth-century Vienna in which
inventors were granted a ten-year right to exclusively offer their inventions [6]. The first
documented case of granting exclusive rights to inventors dates back to the third century
BC, in the ancient Greek city of Sybaris where chefs were granted exclusive rights to
produce their culinary inventions for a year [9]. The formal granting of intellectual
property rights was written into the U.S. Constitution and codified in the Patent Act of
1790 [5]. The law was refined in 1793 and has gone through occasional reform since
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then. Protecting intellectual property on the international front is also gaining increasing
importance. In 1994, the Agreement on Trade Related Aspects of Intellectual Property
Rights (TRIPS) was drafted by the World Trade Organization (WTO) and defines IP
regulation for WTO Members [10].

Constitutional and Statutory Law
The Constitution grants Congress the authority “To promote the Progress of Science and
useful arts by securing for limited Times to Authors and Inventors the exclusive Right to
their respective Writings and Discoveries” [11]. Important revisions to the 1793 law were
passed in 1836 and 1952. The more recent Bayh-Dole Act of 1980, Federal Courts
Improvement Act of 1982, which established the Federal Circuit, and the Hatch-Waxman
Act of 1984, which created the generic drug system by allowing generics to go through
an abbreviated drug application process, have also had significant impacts on overall U.S
policy.

Statutory law stipulates the requirements for patentability: subject matter, novelty,
nonobviousness, disclosure and utility. An invention must also meet the statutory bars,
and an invention cannot be patented if any of the following have occurred more than a
year prior to patent application: the invention is patented or described in a printed
publication available anywhere in the world; the invention is in public use in the United
States; or the invention is on sale in the United States [12].

The United States Patent and Trademark Office (USPTO)
The USPTO is the federal office charged with issuing patents. Approximately 6,000
examiners with expertise in subjects as diverse as chemistry, telecommunications,
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mechanical engineering, nanotechnology and software engineering drive the issuance of
patents [13]. Filers submit an application and pay a fee. An examiner is then assigned to
review the invention in light of statutory requirements, USPTO rules, and court decisions.
The examiner reviews all claimed functions of the invention and communicates back with
the inventor(s) or his or her representatives. Often this is a process of writing and rewriting until the examiner is satisfied the claimed device meets all of the requirements of
patentability [6]. This process is referred to as “prosecution”, not to be confused with the
criminal law definition.
The patent office also holds interference procedures for competing patents filed
near the same time. The U.S. system is unique in the world in that the first inventor to
conceive of the idea has the right to the invention but must prove the point of conception.
The rest of the international community has simplified this process, granting priority to
the first filer, and this is one source of tension that has led to a push to reform the U.S.
system [1]. Patenting is often defined as a race in economic terms, and certainly a first to
file system enhances the sense of urgency for inventors to file an application [14].

The Federal Court System
The U.S. court system hears allegations of infringement and has the final authority to
determine if a patent is valid, or meets all of the criteria for patentability. U.S. District
Courts hear infringement suits and makes declaratory judgment actions related to patents
[5]. The Federal Circuit Court, established in 1982, is the primary court deciding
questions of statutory law involving patent rights and regulations. It serves as appeal
court for cases heard at the District Court level. The Federal Circuit, with its panel of
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expert judges, has largely been left to decide the most important questions of
patentability: defining subject matter and its scope, establishing a test for determining
novelty and obviousness from prior art, and formally construing enablement and utility
[5].
Federal Circuit decisions may be appealed to the U.S. Supreme Court, but since
the creation of the Federal Circuit, the Supreme Court has not granted certiorari in many
patent cases. Thus, Federal Circuit decisions have typically stood as the final word;
however, lately, the Supreme Court has been hearing important cases with serious
implications for patent seekers and holders. By and large, decisions by the Federal Circuit
and the U.S. Supreme Court are applied across all fields of invention. But some cases,
such as the landmark Diamond v. Chakrabarty and pending Association for Molecular
Pathology v. USPTO and Myriad Genetics, Inc., have particular importance for the
biotechnology sectors [15, 16].

Research Universities and Patents
The Bayh-Dole Act mandates that institutions conducting research with federal research
dollars pursue patents on new technologies and license those technologies to private
industry. Other nations have looked toward passing similar legislation in light of the
success of university patenting, however, with success has come unintended
consequences both for the innovation sector and for university researchers, putting the
two at odds at times and contributing to patents on basic research tools that feed patent
thickets [3, 17].
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According to the Association of American Universities, 56% of basic research is
conducted by universities [18]. Since Bayh-Dole passed, the number of patents granted to
universities has climbed from 250 mostly agriculture-related patents per year to over
3,000 in fields that span from biotechnology to superconducting. U.S. universities
collectively now earn almost $2 billion annually from license agreements, but there are
only a few extremely profitable players, such as the University of California system, and
many that struggle to break even [17].
To effectively pursue patents and license marketable technologies to private
industry, universities have set up corporations or foundations that analyze new
inventions, determine whether or not to seek a patent, and then handle the filing of the
patent on behalf of the inventors [7, 8]. Referred to as “technology transfer offices,”
inventors assign their rights to the invention to the university, but then share a percentage
of the revenue with the university. Often a university’s website discloses much of the
process and revenue sharing on their technology office’s website.

The call for reform
A strong patent system results in more patents, and indeed the number of patents pending
in the USPTO has more than doubled in the past ten years [19]. With the influx of
applications has come both obvious and unanticipated problems including increased and
expensive litigation, growing patent backlogs, the issuance of poor and controversial
patents, the rise of non-manufacturing or non-practicing entities, and tension between
generic and research drug manufacturers [19, 1]. Furthermore, the “one-size-fits-all”
model doesn’t allow for the very different climates within the life sciences sector versus
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the tech sector. The issues affecting biotechnology and pharmaceutical research relate to
high costs, long lead start up times, and whether the research is in an academic or clinical
trial setting versus the fast-paced, rapidly evolving software market in which innovations
can be obsolete in as little 18 months. In all industries, the cost of patent litigation has
risen dramatically. The cost of defending a patent in court has risen steadily and can cost
$650,000 to $4.5 million [20].
In technology sectors, the field is crowded, and many technologies are developed
simultaneously by different firms. The cost of litigation and fear of rulings that invalidate
important patents has led to unique problems for tech firms. Google recently bid $900
million for a suite of patents, reportedly to avoid patent litigation [21]. In fact, patent
litigation has become a cottage industry for some. Called non-practicing, or nonmanufacturing entities, these “patent trolls” are companies that search for opportunities to
draft new patents without ever intending to market them. Instead they watch for large
firms to invent similar tools with the intention of suing them for large infringement
awards. This practice runs counter to the very purpose of the patent system, which is to
bring new and useful inventions to market for the public good. The now infamous
Blackberry and eBay cases demonstrate how much large practicing entities have at stake
when they were nearly shut down by non-practicing entities in separate cases [22].
Likewise, the patent backlog has resulted in controversial patents issuing on inventions
that many considered obvious like Amazon’s controversial patent on “one-click” checkouts because overwhelmed examiners may not be as diligent as they could be.
Furthermore, the three year average length of time from application to patent often
renders the technology obsolete, yet technology sectors are caught in a ‘prisoner’s
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dilemma’, forced to defensively patent new technologies despite the fact that doing so is
not in the corporation’s best interest because of the time, cost and sort life expectancy of
tech patents [14, 6].
The life sciences face a different set of problems brought about by the boom in
patents, many of which have been well covered in recent articles, including patent
thickets, that present unique challenges in an industry in which there are multiple
humanitarian consequences for food, vaccine and therapeutic technologies [23]. The
potential for an anticommons effect, first described by Heller and Eisenberg in 1998,
remains and the thought that a company can produce a life-saving technology, or hold the
patent for an important agricultural breakthrough but not produce it, is fraught with
ethical considerations [24].

The America Invents Act
In March 2011, the Senate passed the America Invents Act (S.23) in an attempt to
modernize the patent system. It was the fourth such attempt since 2005. In late April, the
House version of the bill ( H.R.1249 ) passed the House Judiciary Committee and is
expected to pass on the floor in June [25, 26]. The bill has broad, bipartisan support, the
support of major industry groups such as BiO and Phrma, and has been actively
supported by major university groups such the Association of American Universities
(AAU) [1, 18]. Major changes to the law are intended to normalize the U.S. system with
international systems, to reduce the patent backlog with the ultimate goal of having
patents issue within a year of application, and to improve the quality of those patents that
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do issue. Important provisions in the two bills are written with these goals in mind, the
most significant of which are:
The first-to-file provision
Current U.S. law grants patent rights to the first to invent, not the first to file. Moving to a
first-to-file system is retained in the current bill from earlier versions. It normalizes U.S.
law with international standards and is intended to eliminate costly and time consuming
interference proceedings as well as future litigation costs associated with proving the
conception of the invention first. A one-year grace period for disclosure exists in the
legislation, largely at the urging of universities, but a weakness of the bill is that it does
not define disclosure [14, 25]. The grace period and definition of disclosure are of key
importance to university researchers, who must balance the potential for a potentially
patentable (and profitable) new invention with academic priorities for publishing and
advancing their fields of research.
A small, but vocal group of detractors argue the U.S. system is stronger than other
countries because it rewards the inventor instead of the first filer. Further, independent
inventors believe firms would have an advantage under the proposed system, and some
have claimed the new provision is unconstitutional [14].

Third party submission of prior art

The proposed law codifies third party submission of prior art to the USPTO by extending
the period allowed for such submission to six months. By extending the submission
period, it is hoped third parties will have more time to submit evidence that an invention
is obvious [25].
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Elimination of Fee Diversion
The proposed legislation makes several procedural changes for the way the USPTO
operates, the most significant of which being the elimination of fee diversion practices.
Congress currently redirects the fees collected by the USPTO to other Federal programs.
Elimination of fee diversion will allow the USPTO to keep revenues and direct them to
areas of need including hiring more examiners and creating satellite offices to address the
patent backlog [25].

The Courts
The courts play a pivotal role in defining patent eligibility, enforcing issued patents, and
determining validity on questionable patents [6]. The USPTO looks to court decisions to
interpret statutory law and offer clarification of questions such as how to determine
nonobviousness and what constitutes prior art. The most significant changes to patent
law over the past five years have come from the courts. For the first thirty years since the
creation of the Federal Circuit, the Supreme Court was largely silent on patent case law,
presumably to allow the lower court the chance to establish a record of interpretation [5].
Since its creation, the Federal Circuit has heard more than 2,000 appeals. [14] The
Supreme Court has broken its silence as of late and begun reviewing the Federal Courts
decisions and providing guidance on several important issues. Decisions from both courts
are helping to refine and redefine what is patentable in the United States.
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Patentable Subject Matter
Several recent and pending decisions have important implications for the biotechnology
and pharmaceutical sectors. Perhaps the biggest are Bilski v. Kappos, and Myriad
Genetics. In the 1980 landmark case Diamond v. Chakrabarty, in which the Supreme
Court ruled that patentable subject matter extends to “anything under the sun made by the
hand of man” and essentially ruled any invention that is not a product of nature or natural
law was patentable, including living organisms [15]. Thus, ideas cannot be patented, but
transformative processes including those on organisms can be patented. The State Street
Bank v. Signature Financial Group decision extended patentable subject matter to
include business models and allowed for software to be patentable as transformational
steps [27]. The Supreme Court’s decision in Bilski largely abandons State Street, making
certain business models unpatentable, but upholding the important machine or
transformation test for subject matter. However, the court clarifies that this is not the sole
test patentable subject matter. The decision eliminates patents on business models and
may have implications for software patents, but it paved the way for a new test for
patentability in cases such as optimized vaccine schedules or diagnostic tests that
measure natural phenomenon but require an inventive step [28].
The Myriad case, which is being closely watched by industry and academics
alike, is currently being heard by the Federal Circuit after a lower court, with the urging
of the Department of Justice, ruled that patents on isolated, purified genes amounted to a
“lawyer’s trick” and are ineligible as a product of nature. The patents on the breast cancer
genes BRCA1 and BRCA2 have generated a host of ethical considerations, and the case
has profound implications for all of the life sciences since the ruling would apply not
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only to genes, but to proteins, cell lines, and antibodies [27]. Analysts expect the Federal
Circuit to overturn the lower court’s decisions, but most observers anticipate that the case
will ultimately end up in the Supreme Court.

Obviousness

Probably the hardest test for a new invention to meet is the standard of nonobviousness.
The 2007 Supreme Court ruling in KSR Int'l Co. v. Teleflex Inc. created a standard for the
courts to make determinations about what someone of “ordinary skill in the art” would
find obvious to do [29]. In other words, what prior art would another inventor in the same
field look toward to solve a particular problem? Also, the In re Kubin ruling by the
Federal Circuit in 2009 changed the obviousness rule significantly for biotechnology
patents. The Kubin decision found that a known protein renders its related gene obvious
since the protein suggested its function, and the methods for finding and isolating the
gene are well-known [30].

Utility and Enablement

Biotechnology patents must also meet a more stringent rule of utility. In other disciplines,
the standard is low enough to be presumed; however, biotechnology patents are not
issued on expressed sequence tags (ESTs) because an EST cannot be used to determine
the purpose and use of the gene it helps locate. The Federal Circuit’s 2005 In re Fisher
case found that patents on DNA fragments had to amount to more than a “hunting
license” and demonstrate “specific and substantial utility.” [32]. Likewise, the 2010 Ariad
v. Lilly decision addressed the disclosure and enablement requirements, and reminiscent
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of the Fisher decision, the court essentially found that an inventor cannot claim genus if
only a few species are described solely because there are certain to be more species to be
discovered [33].

What it means for university research
The courts and the proposed changes to patent laws show continued support for a strong
and functioning patent system, important for the long-lead times facing biotech and
pharmaceutical patents. Recent higher court decisions show continued support for
biotechnology and pharmaceutical innovation, but with tougher and narrower standards
for meeting the criteria of patentability. The courts appear to be deliberately working to
tighten claim construction and demand precision in biotechnology in ways that address
broad, over-reaching and obvious patents that harm all sectors. Far from settled, new
legislation, if it passes the house and the two bills can be reconciled, will be heard and
refined through the courts as researchers and their institutions work to find a balance
between an academic mission with its emphasis on early publishing and the imperative to
get new technologies into the private sector and bring those goods to market. For now,
university researchers would do well to follow the Myriad case closely as well as watch
developments and interpretations of the currently proposed reform legislation. Probably
the most important point for inventors to watch is the year-long grace period for
disclosure. Early disclosure to the university technology transfer office means that
licensing experts can begin analyzing potentially important inventions even while the
researcher begins to work on writing publishable results. Good resources for the
interested researcher can be found at uspto.gov, autm.org, patentlyo.com, aau.org and his
or her own institution’s technology transfer Web site.
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Unintended Consequences: Final Conclusions and Considerations

When I embarked on an inquiry into the role of patents in agricultural biotechnology five
years ago, it was with the assumption that humanitarian problems arising from the
patenting of food technologies was perhaps the most important threat arising from the
particular problems facing the U.S. patent system. Direct and deliberate focus revealed a
host of more practical, definable issues resulting from backlogs in the USPTO: poor
patents quality, the rise of predatory litigation, and the implications of private and public
investment in research driven by the innovation sector. Solving those practical and
procedural issues have great capacity for lasting ability to serve “the greater good” as it
relates to food and medicine.
One of the biggest surprises in the past five years which helped focus my line of
inquiry was the lack of emerging humanitarian issues on the agricultural side of
biotechnology. Despite well-documented problems in the well-known Golden Rice case,
few new instances of humanitarian crop development arose specifically because of patent
thickets. This was due largely to the fact that the EU and Africa remain suspicious of
transgenic crop production. It is unlikely that engineered humanitarian crops will have
the opportunity to solve global or sub-Saharan hunger with extreme opposition to the
import of these crops. Still, the potential for similar cases remains and as world
population continues to grow toward a projected 2050 peak. Increased demand for food
could erase or diminish the taboo on transgenics. Fortunately, two focused and dedicated
non-profit groups have been looking extensively at humanitarian issues related to the
patenting of crop biotechnologies. PIPRA and CAMBIA remain committed to studying
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this issue and providing workaround solutions that eliminate barriers to improved food
technologies.
The ethical considerations for the biomedical side of the coin; however, continue
to expand with important implications for biotechnology. The looming “patent cliff” for
big manufacturers (several drug companies’ patents on blockbuster drugs are set to expire
in the next two years), decreased research and development (R&D), and increased
pressure for affordable medicines and vaccines will likely demand focused policy
analysis and reform in the coming decade—particularly in light of population growth,
increased globalization and in this country, the aging of the baby-boomers.
What becomes clearer through focused research is that the anticipated fears of
environmental groups has been misapplied. The advent and widespread adoption of
biotechnologies has not resulted in environmental disaster, but instead the unintended
consequences and most-pressing ethical considerations become those of economics and
policy.
The patent backlog threatens to undermine the very foundation of American
research—the notion that we should invest new inquiry in undiscovered paths so that new
discovery can serve the public good. Patents have helped drive private and public
investments that improve, enhance and prolong life. Indeed the success of the U.S. patent
system in some ways has ironically become its biggest problem. New research
investment dollars from corporations and industry has demanded the ‘guarantee’ of
protected, exclusive rights to intellectual property, yet the mire of unresolved patent
applications in the USPTO has left many inventors in limbo, unable to market new
products with confidence, especially in the tech sectors where their ideas may be obsolete
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before they come to market. In the life sciences, failure to invest in or market known
technologies might mean the difference in life-saving bird flu or HIV vaccines or new
diagnostic tests for potentially fatal E.coli strains or worse. The Myriad Genetics case
will have consequences both good and bad that reverberate for decades.
The main conclusion that must be drawn is that the courts cannot solve the array
of problems facing the innovation in the U.S.—Congress knows it must step in, and the
Obama administration has made a significant push to make certain legislation succeeds
this time around. Still, with a Senate bill passed and the House version due for a vote this
year, there are no guarantees that this Congress will be able to reconcile the two versions
of the law and pass comprehensive reform. Even then, it could be years before the
impacts of legislation and new court rulings play out in the innovation sectors. What has
emerged over the past five years is a clear picture that innovation, one of the primary
economic goods in an information market, is most threatened by its own boom. U.S.
legislators must make important changes to free resources need to meet increasing
demand. Still, it is ominous our legal and legislative system continues to lag behind
human innovation and appears ill-equipped to handle the pace and gravity of
technological advances. Not surprisingly, the pressure for reform has not come from the
ethical and humanitarian considerations that arise from ownership of the building blocks
of life, but from corporate and university interests with the very practical need to get
meaningful patents on new discoveries. Now, more than ever, researchers and
universities must stay informed and active in intellectual property policy and embrace
their public mission to ensure that research is driven by ethical and humanitarian
considerations in addition to economic ones.
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